Navigation Links
HS-7 Document Regarding Research @ M. D. Anderson Orlando
Date:9/3/2009

GREENVILLE, S.C., Sept. 3 /PRNewswire/ -- HS Pharmaceuticals, LLC and its business partner 7 Oaks Pharmaceutical Corporation have engaged in a collaborative research agreement with M. D. Anderson Cancer Center Orlando to study the effects of its proprietary and patented research compound, HS-7, as an effective treatment for pancreatic cancer. The first preclinical study has shown encouraging results and additional studies are now underway.

The research was conducted by Dr. Cheryl Baker, Director and Assistant Professor, Cancer Research Institute of M. D. Anderson Cancer Center Orlando. In a double-blinded study, HS-7 was injected into nude mouse models impregnated with human pancreatic cancer tissue. Reported results indicate that HS-7 demonstrated promising anti-cancer activity. Dr. Baker will continue with the next phase of preclinical studies and M. D. Anderson Cancer Center Orlando will work with HS Pharmaceuticals, LLC and 7 Oaks Pharmaceutical Corporation to progress the HS-7 compound into Phase 1 clinical trials for pancreatic cancer.

The companies have also contracted with Dr. Thomas Wagner (Director, Oncology Research Institute, Greeneville Hospital System) and Dr. Gunter Schwamberger (Professor, University of Salzburg, Austria) to research additional oncology applications for HS-7. Dr. Wagner and Dr. Schwamberger are now conducting animal studies on the compound's effect in melanoma, lymphoma, leukemia, and sarcoma models.


'/>"/>
SOURCE HS Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. University of Redlands Student Cody Unser Documentary Run to Start Today in L.A.
2. Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use
3. Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
4. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
5. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
8. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
9. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
10. MannKind Addresses Pfizers Announcement Regarding Exubera
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):